Media headlines about Cronos Group (NASDAQ:CRON) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cronos Group earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 43.2184121385587 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- MedMen Leaps Into Canadian Cannabis Market For Joint Venture With Cronos Group (forbes.com)
- Boom! Canadian Marijuana Stocks Just Got a Little Less Risky (finance.yahoo.com)
- Cronos Group Upping Its Branding Game – Could Pay Off In The Long Term – Seeking Alpha (seekingalpha.com)
- Cronos Group Inc. Announces $100 Million Bought Deal – PR Newswire (press release) (prnewswire.com)
- BRIEF-Cronos Group Files For Stock Shelf Of Up To $87.9 Mln (reuters.com)
Cronos Group stock opened at $7.47 on Friday. Cronos Group has a 12 month low of $1.00 and a 12 month high of $11.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.54 and a current ratio of 4.92.
COPYRIGHT VIOLATION WARNING: “Cronos Group (CRON) Getting Somewhat Favorable News Coverage, Analysis Shows” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3299156/cronos-group-cron-getting-somewhat-favorable-news-coverage-analysis-shows.html.
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.